Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanidatamab + fluorouracil + leucovorin + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a fixed combination therapy consisting of **zanidatamab**, a bispecific monoclonal antibody targeting two distinct epitopes on the extracellular domain of HER2, together with **fluorouracil**, **leucovorin**, and **oxaliplatin**, classic agents used in colorectal and gastrointestinal cancer chemotherapy protocols (notably "mFOLFOX6"). Zanidatamab exerts anti-tumor activity through HER2 signal blockade, induction of complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, phagocytosis, HER2 internalization, and downregulation. The regimen is under active clinical investigation primarily for HER2-positive advanced or metastatic gastroesophageal adenocarcinoma. The antibody portion (zanidatamab) is developed by Zymeworks and Jazz Pharmaceuticals. The combination is administered intravenously.
- Other names
- mFOLFOX6mFOLFOX-6mFOLFOX 6
02
Targets
DNATS (Thymidylate synthase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on zanidatamab + fluorouracil + leucovorin + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanidatamab + fluorouracil + leucovorin + oxaliplatin.